¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Receptor, Nerve Growth Factor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 4
¿µ¹® sural nerve ÇÑ±Û ÀåµýÁö½Å°æ
¼³¸í   
  ¾ÈÂÊÀåµýÁöÇǺνŰ根נ¿ÂÀåµýÁö½Å°æÀÇ ±³ÅëÁö¿¡¼­ ½ÃÀÛÇÏ¿© °¡ÂʹèÂÊÇǺνŰ根נ°¡Âʹ߲ÞÄ¡°¡ÁöÀÇ °¡Áö¸¦ ³½´Ù. ³Ò´Ù¸® µîÂÊÀÇ ÇǺÎ, ¹ß²ÞÄ¡¿Í ¹ßÀÇ °¡ÂÊÀÇ ÇǺΠ¹× °üÀý¿¡ ºÐÆ÷Çϸç, ÀϹݠ°¨°¢¼º ±â´ÉÀ» ÇÑ´Ù. 
¿µ¹® spinal nerve ÇÑ±Û Ã´¼ö½Å°æ
¼³¸í   
  Ã´¼öÀÇ ¾Õ»Ô¿¡¼­ Ãâ¹ßÇϴ ¿îµ¿½Å°æ°ú µÞ»ÔÀ¸·Î µé¾î¿À´Â °¨°¢½Å°æÀÌ ÇÕÃļ­ Çü¼ºµÇ´Â ½Å°æÀ¸·Î¼­ ÃÑ 31½ÖÀÌ Á¸ÀçÇÔ. ¸ñ»À½Å°æÀÌ 8½Ö, ÀÚµî»À½Å°æÀÌ 12½Ö, Ç㸮»ÀÀÇ ½Å°æÀÌ 5½Ö, ¾ûÄ¡»ÀÀÇ 6½ÖÀ» ÀÌ·ë.
¿µ¹® auditory nerve ÇÑ±Û Ã»½Å°æ
¼³¸í   
  ±Í¿¡¼­ °¨ÁöµÈ Ã»°¢ÀÇ ½ÅÈ£¸¦ ´ë³ú·Î º¸³»´Â ¿ªÇÒÀ» Çϴ ½Å°æ. ´ÞÆØÀ̽Űæ¶ó°í ºÒ¸®±âµµ ÇÑ´Ù. ±×°ÍÀº ¼Ò¸®¸¦ Àü±âÀû ½ÅÈ£·Î ¹Ù²Ù¾î ½Å°æÀ¸·Î Àü´ÞÇØ Áִ ´ÞÆØÀÌÀÇ Áý°°ÀÌ »ý±ä ±â°üÀ» ´ÞÆØÀ̶ó°í ºÎ¸£±â ¶§¹®ÀÌ´Ù.
  
  Ã»½Å°æ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • growth regulator
    ¼ºÀåÁ¶ÀýÀÎÀÚ
  • growth retardation
    ¹ßÀ°Áö¿¬, ¼ºÀåÁö¿¬
  • growth spurt
    ¼ºÀå±ÞÁõ
  • growth zone
    ¼ºÀ屸¿ª, ¼ºÀå´ë
  • growth-onset diabetes
    ¹ßÀ°±â¹ßº´´ç´¢º´, Ãʱâ´ç´¢º´
  • intrauterine growth restriction
    Àڱ󻼺ÀåÁ¦ÇÑ
  • intrauterine growth retardation
    Àڱ󻼺ÀåÁö¿¬
  • isometric growth
    µîÀ强¼ºÀå
  • infiltrative growth
    ħÀ±¼ºÀå
  • interstitial growth
    »çÀÌÁú¼ºÀå, °£Áú¼ºÀå
  • maximal growth rate
    ÃÖ´ëÁõ½Ä·ü, Ãִ뼺Àå·ü
  • one step growth
    ÀϴܰèÁõ½Ä
  • one step growth curve
    ÀϴܰèÁõ½Ä°î¼±
  • organotypic growth
    ±â°üÇüÀû¼ºÀå
  • specific growth rate
    ƯÀÌÁõ½Ä·ü, ƯÀ̼ºÀå·ü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • axillary nerve
    °Üµå¶û½Å°æ
  • cranial nerve
    ³ú½Å°æ
  • facial nerve
    ¾ó±¼½Å°æ
  • glossopharyngeal nerve
    ÇôÀενŰæ
  • great auricular nerve
    Å«±Ó¹ÙÄû½Å°æ
  • hypoglossal nerve
    Çô¹Ø½Å°æ
  • inferior laryngeal nerve
    ¾Æ·¡ÈĵνŰæ
  • median nerve
    Á¤Á߽Űæ
  • motor nerve
    ¿îµ¿½Å°æ
  • oculomotor nerve
    ´«µ¹¸²½Å°æ
  • olfactory nerve
    Èİ¢½Å°æ
  • optic nerve
    ½Ã°¢½Å°æ
  • parasympathetic nerve
    ºÎ±³°¨½Å°æ
  • peripheral nerve
    ¸»ÃʽŰæ
  • peroneal nerve
    Á¾¾Æ¸®½Å°æ, ºñ°ñ½Å°æ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • joint receptor
    °üÀý¼ö¿ë±â
  • kinesthetic receptor
    ¿îµ¿°¨°¢¼ö¿ëü
  • labyrinthine receptor
    ¹Ì·Î¼ö¿ëü
  • muscarinic receptor
    ¹«½ºÄ«¸°¼ö¿ëü
  • neuromuscular receptor
    ½Å°æ±ÙÀ°¼ö¿ëü
  • nicotinic receptor
    ´ÏÄÚÆ¾¼ö¿ëü
  • olfactory receptor
    Èİ¢¼ö¿ëü
  • opiate receptor
    ¾ÆÆí¼ö¿ëü
  • opioid receptor
    ¾ÆÆíÀ¯»ç¹°Áú¼ö¿ëü
  • paciniform receptor
    ÆÄÄ¡´ÏÇü¼ö¿ëü
  • postsynaptic receptor
    ¿¬Á¢Èļö¿ëü
  • prejunctional neuromuscular receptor
    ½Å°æ±ÙÀ°Á¢ÇÕÀü¼ö¿ëü
  • pressor receptor
    ¾Ð·Â¼ö¿ëü
  • receptor potential
    °¨¼ö±âÀüÀ§, °¨¼ö±âÀü¾Ð, ¼ö¿ëüÀü¾Ð
  • receptor
    ¼ö¿ëü, ¼ö¿ë±â
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • alpha-adrenergic receptor
    ¾ËÆÄ-¾Æµå·¹³¯¸°¼ö¿ëü.
  • alpha-adrenergic receptor
    ¾ËÆÄ¾Æµå·¹³¯¸°¼ö¿ëü
  • androgen receptor
    ³²¼ºÈ£¸£¸ó ¼ö¿ëü
  • antigen binding receptor
    Ç׿ø°áÇÕ¼ö¿ëü
  • antigen receptor
    Ç׿ø¼ö¿ëü.
  • homing receptor
    ±Í¼Ò¼ö¿ëü
  • immunoglobulin receptor
    ¸é¿ª±Û·ÎºÒ¸° ¼ö¿ëü
  • insulin receptor
    Àν¶¸°¼ö¿ëü(áôé»ô÷).
  • insulin receptor
    Àν¶¸°¼ö¿ëü.
  • platelet receptor
    Ç÷¼ÒÆÇ¼ö¿ëü
  • postsynaptic receptor
    ¿¬Á¢Èļö¿ëü
  • prejunctional neuromuscular receptor
    ½Å°æ±ÙÁ¢ÇÕÀü¼ö¿ëü
  • pressor receptor
    ¾Ð·Â¼ö¿ëü(äâæ³áôé»ô÷).
  • pressor receptor reflex
    ¾Ð·Â¼ö¿ëü¹Ý»ç(äâæ³áôé»ô÷ÚãÞÒ).
  • pressure receptor
    ¾Ð¼ö¿ë±â, ¾Ð·Â¼ö¿ëü(¡­áôé»ô÷).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • antigen binding receptor
    Ç׿ø°áÇÕ¼ö¿ëü
  • antigen receptor
    Ç׿ø¼ö¿ëü.
  • benzodiazepine receptor agonists(s)
    º¥Á¶´ÙÀ̾ÆÁ¦ÇÉ ¼ö¿ëü ÀÛ¿ëÁ¦
  • benzodiazepine receptor antagonist(s)
    º¥Á¶´ÙÀ̾ÆÁ¦ÇÉ ¼ö¿ëü ±æÇ×Á¦
  • benzodiazepine receptor(s)
    º¥Á¶´ÙÀ̾ÆÁ¦ÇÉ ¼ö¿ëü
  • beta adrenergic receptor
    º£Å¸¾Æµå·¹³¯¸°¼º ¼ö¿ëü(¼ö¿ë±â, °¨¼öü)
  • beta receptor
    º£Å¸ ¼ö¿ëü(¼ö¿ë±â, °¨¼öü, °¨¼ö±â)
  • beta receptor blocker
    º£Å¸¼ö¿ëü Â÷´ÜÁ¦( -áôé»ô÷ ó´Ó¨ð¥)
  • beta receptor stimulating agent
    º£Å¸¼ö¿ëü ÀÚ±ØÁ¦( -áôé»ô÷ í©Ð½ð¥)
  • beta-ARK : beta-adrenergic receptor kinase
    º£Å¸-¾Æµå·¹³¯¸°(¼º)¼ö¿ëü ÀλêÈ­È¿¼Ò.
  • beta-adrenergic receptor
    º£Å¸ ¾Æµå·¹³¯¸°¼º ¼ö¿ëü
  • cardiac receptor
    ½ÉÀå¼ö¿ëü(ãýíôáôé»ô÷)
  • cell surface receptor
    ¼¼Æ÷Ç¥¸é¼ö¿ëü
  • cholinergic receptor
    Äݸ°(ÀÛµ¿)¼º ¼ö¿ëü(¼ö¿ë±â, °¨¼ö±â)
  • cold receptor
    ³Ã°¢¼ö¿ëü(Ò²ÊÆáôé»ô÷)(¼ö¿ë±â, °¨¼ö±â)
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • Long ciliary nerve
    ±ä¼¶¸ðü½Å°æ
    [¿¾ ¿ë¾î] Àå¸ð¾çü½Å°æ
  • Long nasopalatine nerve
    ±äÄÚÀÔõÀå½Å°æ
    [¿¾ ¿ë¾î] Àåºñ±¸°³½Å°æ
  • Deep petrosal nerve
    ±íÀº¹ÙÀ§½Å°æ
    [¿¾ ¿ë¾î] ½ÉÃßü½Å°æ
  • Deep peroneal nerve
    ±íÀºÁ¾¾Æ¸®½Å°æ
    [¿¾ ¿ë¾î] ½Éºñ°ñ½Å°æ
  • Masseteric nerve
    ±ú¹°±Ù½Å°æ
    [¿¾ ¿ë¾î] ±³±Ù½Å°æ
  • Coccygeal nerve
    ²¿¸®½Å°æ
    [¿¾ ¿ë¾î] ¹Ì°ñ½Å°æ
  • Nerve of pterygoid canal [Facial root]
    ³¯°³°ü½Å°æ [¾ó±¼½Å°æ»Ñ¸®]
    [¿¾ ¿ë¾î] À͵¹°ü½Å°æ
  • Nerve to quadratus femoris
    ³Ò´Ù¸®³×¸ð±Ù½Å°æ
    [¿¾ ¿ë¾î] ´ëÅð¹æÇü±Ù½Å°æ
  • Femoral nerve
    ³Ò´Ù¸®½Å°æ
    [¿¾ ¿ë¾î] ´ëÅð½Å°æ
  • Radial nerve
    ³ë½Å°æ
    [¿¾ ¿ë¾î] ¿ä°ñ½Å°æ
  • Groove for radial nerve
    ³ë½Å°æ°í¶û
    [¿¾ ¿ë¾î] ¿ä°ñ½Å°æ±¸
  • Sensory ganglia of cranial nerve [Cranial ganglia]
    ³ú½Å°æÀý
    [¿¾ ¿ë¾î] ³ú½Å°æÀý
  • Craniospinal nerve
    ³úô¼ö½Å°æ
    [¿¾ ¿ë¾î] ³úô¼ö½Å°æ
  • Lacrimal nerve
    ´«¹°»ù½Å°æ
    [¿¾ ¿ë¾î] ´©¼±½Å°æ
  • Opthalmic nerve
    ´«½Å°æ
    [¿¾ ¿ë¾î] ¾È½Å°æ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • balanced growth
    ±ÕÇü¼ºÀå(гû¬à÷íþ)
  • chain-growth polymer
    »ç½½½ÅÀå(ãßíþ)ÁßÇÕü(ñìùêô÷)
  • comb growth test
    °è°ü ¼ºÀå½ÃÇè(ͮήà÷íþãËúÐ)
  • confluent growth
    Àü¸é¼ºÀå(îïØüà÷íþ)
  • density-dependent growth
    "¹ÐµµÀÇÁ¸ ¼ºÀå(ÚËÓøëîðíà÷íþ), (ÔÒ) contact inhibition"
  • exponential growth
    Áö¼ö ¼ºÀå (ò¦â¦à÷íþ)
  • exponential growth rate constant
    Áö¼ö ¼ºÀå¼Óµµ »ó¼ö (ò¦â¦à÷íþáÜÓøßÈâ¦)
  • fibroblast growth factors
    ¼¶À¯¾Æ¼¼Æ÷ ¼ºÀÚÀÎÀÚ (àéë«ä´á¬øàà÷íþì×í­)
  • growth curve
    ¼ºÀå°î¼± (à÷íþÍØàÊ)
  • growth hormone
    ¼ºÀå(à÷íþ)È£¸£¸ó
  • growth hormone regulatory hormone
    ¼ºÀå(à÷íþ)È£¸£¸ó Á¶Àý(ðàï½) È£¸£¸ó
  • growth hormone release-inhibiting hormone
    ¼ºÀå(à÷íþ) È£¸£¸ó ¹æÃâÀúÇØ (Û¯õóîÁúª) È£¸£¸ó
  • growth hormone releasing hormone
    ¼ºÀå(à÷íþ)È£¸£¸ó ¹æÃâ (Û¯õó)È£¸£¸ó
  • growth medium
    ¼ºÀå¹èÁö (à÷íþÛÆò¢)
  • growth rate constant
    ¼ºÀå¼Óµµ »ó¼ö (à÷íþáÜÓøßÈâ¦)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • nerve stretching
    ½Å°æ½Å¿¬(¼ú)
  • nerve transmitter substance
    ½Å°æÀü´Þ¹°Áú
  • oculomotor nerve
    µ¿¾È½Å°æ
  • olfactory nerve
    Èİ¢½Å°æ
  • ophthalmic nerve
    ´«½Å°æ, ¾È½Å°æ
  • optic nerve
    ½Ã½Å°æ
  • optic nerve atrophy
    ½Ã½Å°æÀ§Ãà
  • parasympathetic nerve
    ºÎ±³°¨½Å°æ
  • peripheral nerve
    ¸»ÃʽŰæ
  • peroneal nerve
    ºñ°ñ½Å°æ
  • phrenic nerve
    Ⱦ°Ý½Å°æ
  • pudendal nerve
    À½ºÎ½Å°æ
  • radial nerve
    ¿ä°ñ½Å°æ
  • recurrent nerve
    µÇµ¹À̽Űæ, ¹Ýȸ½Å°æ
  • sciatic nerve
    Á°ñ½Å°æ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
NGFB nerve growth factor beta
NGFG nerve growth factor gamma
NGFIA nerve growth factor-induced clone A
NGFIC nerve growth factor-induced clone C
ER efficiency ratio; epigastric region; ejection rate; electroresection; emergency room; endoplasmic re...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
EGFR Epidermal growth factor , EGF receptor
FGFR Fibroblast Growth Factor Receptor
FGFR1 Fibroblast Growth Factor Receptor 1
FGFR2 Fibroblast growth factor receptor 2
FGFR3 Fibroblast growth factor receptor 3
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • dominant receptor
    ¿ì¼º ¼ö¿ëü
  • dopamine receptor
    µµÆÄ¹Î ¼ö¿ëü
  • down-regulation of receptor
    ¼ö¿ëü ÇÏÇâ Á¶Àý
  • drug receptor
    ¾à¹° ¼ö¿ëü
  • estrogen receptor protein
    ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ´Ü¹éÁú
  • Fc receptor
    Fc ¼ö¿ëü
    Ç×üÀÇ Fc ºÐÀý°ú °áÇÕÇÏ´Â ¼¼Æ÷ Ç¥¸é ¼ö¿ëüÀ̸ç B ¼¼Æ÷, macro
  • free receptor
    À¯¸® ¼ö¿ëü
  • image receptor
    »ó ¼ö¿ë±â
  • k receptor
    k ¼ö¿ë±â
  • kapa receptor
    Ä«ÆÄ ¼ö¿ëü
  • ligand receptor binding
    ¸®°£µå ¼ö¿ë±â °áÇÕ
  • multiple somatic receptor
    ´Ù¹ß¼º ü ¼ö¿ëü, ´Ù¹ß¼º ü ¼ö¿ë±â
  • opiate analgesia receptor
    ¾ÆÆí¼º ÁøÅë ¼ö¿ëü, ¾ÆÆí¼º ÁøÅë ¼ö¿ë±â
  • opiate receptor
    ¾ÆÆí ¼ö¿ëü, ¾ÆÆí ¼ö¿ë±â
    1. ¥ì : ¥ì1Àº µ¿Åë Á¶Àý ¾àÁ¦°¡ °áÇÕ, ¥ì2¿Í °áÇսô ȣÈíÀÌ ¾ïÁ¦µÈ´Ù. 2. ¥ê¿Í °áÇÕ ½Ã Â÷ºÐÇØÁø´Ù. 3. ¥ä : ¸ö¿¡¼­ »ý¼ºµÇ´Â ³»Àμº o
  • peripheral receptor
    ¸»ÃÊ ¼ö¿ëü, ¸»ÃÊ ¼ö¿ë±â
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
fibroblast growth factor, acidic <chemical> A growth factor which has been isolated from a variety of cells. It contains 154 amino acid residues and has potent heparin-binding activity. Heparin potentiates the biological activities of afgf. The growth factor is an extremely potent inducer of DNA synthesis in a variety of normal diploid mammalian cell types from mesoderm and neuroectoderm lineages and also has chemotactic and mitogenic activities.
Chemical name: Fibroblast growth factor (human brain acidic protein moiety reduced)
(12 Dec 1998)
fibroblast growth factor, basic A single-chain polypeptide of approximately 15-16 kD which has been isolated from a variety of cells. It has a 55% amino acid residue identity to acidic fibroblast growth factor and has potent heparin-binding activity. However, in contrast to the acidic fibroblast growth factor, heparin does not potentiate the biological activities of bfgf. The growth factor is an extremely potent inducer of DNA synthesis in a variety of normal diploid mammalian cell types from mesoderm and neuroectoderm lineages and promotes cellular differentiation in vitro.
(12 Dec 1998)
nerve growth cone <cell biology> A specialised region at the tip of a growing neurite that is responsible for sensing the local environment and moving toward the neuron's target cell. Growth cones are hand shaped, with several long filopodia that differentially adhere to surfaces in the embryo. Growth cones can be sensitive to several guidance cues, for example: surface adhesiveness, growth factors, neurotransmitters and electric fields (galvanotropism).
(18 Nov 1997)
nerve growth factors Factors which enhance the growth potentialities of sensory and sympathetic nerve cells.
(12 Dec 1998)
communicating branches of auriculotemporal nerve to facial nerve <anatomy, nerve> Branches conveying fibres from the auriculotemporal nerve to the facial nerve.
Synonym: rami communicantes nervi auriculotemporalis cum nervo faciali.
(05 Mar 2000)
communicating branches of lingual nerve to hypoglossal nerve <anatomy, nerve> Communicating branches between the lingual nerve (from mandibular nerve) and hypoglossal nerve forming a plexus on the hypoglossus muscle.
Synonym: rami communicantes nervi lingualis cum nervo hypoglosso.
(05 Mar 2000)
communicating branch of facial nerve with glossopharyngeal nerve <anatomy, nerve> A small branch from the digastric branch of the facial nerve to the glossopharyngeal nerve.
Synonym: ramus communicans cum nervo glossopharyngeo, Haller's ansa.
(05 Mar 2000)
communicating branch of glossopharyngeal nerve with auricular branch of vagus nerve <anatomy, nerve> A small branch of the glossopharyngeal nerve which joins the auricular branch of the vagus, conveying tactile fibres.
Synonym: ramus communicans cum nervo glossopharyngeo, ramus communicans nervi glossopharyngei cum ramo auriculari nervi vagalis.
(05 Mar 2000)
communicating branch of lacrimal nerve with zygomatic nerve <anatomy, nerve> Nerve branch by which postsynaptic parasympathetic (secretomotor) fibres from the pterygopalatine ganglion are transferred from the zygomatic nerve to the lacrimal nerve (heretofore purely sensory) for distribution to the lacrimal gland.
Synonym: ramus communicans nervi lacrimalis cum nervo zygomatico.
(05 Mar 2000)
communicating branch of median nerve with ulnar nerve <anatomy, nerve> Branch of median nerve joining the ulnar nerve in the hand; the anterior interosseous branch of the median nerve may also communicate with the ulnar nerve in the proximal forearm.
Synonym: ramus communicans nervi mediani cum nervo ulnari.
(05 Mar 2000)
communicating branch of superior laryngeal nerve with recurrent laryngeal nerve <anatomy, nerve> Branch of internal branch of superior laryngeal nerve communicating with the recurrent laryngeal nerve in the wall of the laryngopharynx supplying sensory fibres to the latter.
Synonym: ramus communicans nervi laryngei recurrentis cum ramo laryngeo interno, ramus communicans nervi laryngei superioris cum nervo laryngeo recurrenti, Galen's anastomosis, Galen's nerve.
(05 Mar 2000)
acetylcholine receptor antibodies <neurology, investigation> A test used to measure the amount of antibodies to acetylcholine receptors on nerve endings. This is a diagnostic test for myasthenia gravis. A normal value is no antibodies in the bloodstream.
Acetylcholine receptor (AChR) binding autoantibodies (i.e. Antibodies reactive with several epitopes other than the binding site for acetylcholine or alpha-bungarotoxin) are present in approximately 88% of patients with generalised myasthenia gravis, 70% of ocular myasthenia and in approximately 80% of myasthenia gravis in remission.
Although serum concentrations of AChR binding autoantibodies do not in general correlate well with severity of weakness, there is typical decrease in concentration as weakness improves with immunosuppressive therapy.
AChR blocking autoantibodies (i.e., antibodies reactive with the AChR binding site) are present in about 50% of patients with myasthenia gravis, 30% with ocular myasthenia gravis and 20% of myasthenia gravis in remission, AChR blocking autoantibodies are the only AChR autoantibodies present in about 1% of myasthenia gravis.
AChR modulating autoantibodies (i.e., autoantibodies which cross-link AChRs and cause their removal from muscle membrane surfaces) are present in more than 90% of myasthenia gravis and occasionally are the only AchR autoantibodies detectable in mild, recent onset or ocular-restricted myasthenia gravis.
Results for AChR modulating autoantibodies can be transiently false-positive due to curare-like drugs used during general anesthesia. AChR autoantibodies of one or more types are found in at least 80% of ocular myasthenia gravis.
Although generally absent in neurological conditions other than myasthenia gravis(and consequently unlikely to cause confusion in neurodiagnosis), false-positive results for AChR autoantibodies occasionally occur in primary biliary cirrhosis, tardive dyskinesia, autoimmune thyroiditis, the elderly, amyotrophic lateral sclerosis patients treated with cobra venom and patients with thymoma in the absence of myasthenia gravis. Approximately 1% of patients with rheumatoid arthritis treated with D-penicillamine develop AChR autoantibodies and myasthenia gravis, both of which disappear when the drug is discontinued.
Babies born to ~10% of myasthenia gravis mothers have a transient neonatal form of myasthenia gravis that responds well to anticholinesterase therapy and usually remits within 1 month as maternal IgG disappears.
(29 Dec 1997)
amino acid receptor <biochemistry> Ligand gated ion channels with specific receptors for amino acid transmitters. An extended protein superfamily that also includes subunits of the nicotinic acetylcholine receptor.
(18 Nov 1997)
AMPA receptor <cell biology> Glutamate operated ion channel.
See: excitatory amino acid receptor channels.
(05 Feb 1998)
ANP receptor <molecular biology> Family of 3 receptors for atrial natriuretic peptide. ANP A and ANP B have intracellular guanylate cyclase and protein kinase like domains. ANP C, shares the extracellular ligand binding and transmembrane domains, but lacks the functional intracellular domains and is not thought to be involved in signal transduction.
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • nerve impulse
    (»ý¸®)½Å°æÃæ°Ý(ÀÚ±Ø)
  • nerve trunk
    ½Å°æ¿øÁÙ±â;½Å°æ°£
  • nerve war
    X;½Å°æÀü;¼±ÀüÀü(cf.COLD WAR,SHOOTING WAR)
  • ninth cranial nerve
    ¼³ÀÎ ½Å°æ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á